{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:22:20Z","timestamp":1791516140815,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11255-019-02232-z","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T09:02:31Z","timestamp":1564218151000},"page":"1903-1911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Organ-sparing procedures in GU cancer: part 3-organ-sparing procedures in urothelial cancer of upper tract, bladder and urethra"],"prefix":"10.1007","volume":"51","author":[{"given":"Mahmoud I.","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Alliston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Bauer-Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil K.","family":"Bissada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-1000","authenticated-orcid":false,"given":"Mohamed H.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"issue":"1","key":"2232_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2232_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.juro.2010.03.030","volume":"184","author":"JC Brien","year":"2010","unstructured":"Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD (2010) Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 184(1):69\u201373. \n                    https:\/\/doi.org\/10.1016\/j.juro.2010.03.030","journal-title":"J Urol"},{"issue":"4","key":"2232_CR3","first-page":"359","volume":"68","author":"JD Raman","year":"2016","unstructured":"Raman JD (2016) Kidney sparing surgery for upper-tract urothelial carcinoma. Minerva urologica e nefrologica (Ital J Urol Nephrol) 68(4):359\u2013371","journal-title":"Minerva urologica e nefrologica (Ital J Urol Nephrol)"},{"issue":"3","key":"2232_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/end.2017.0915","volume":"32","author":"G Musi","year":"2018","unstructured":"Musi G, Mistretta FA, Marenghi C, Russo A, Catellani M, Nazzani S, Conti A, Luzzago S, Ferro M, Matei DV, Carmignani L, de Cobelli O (2018) Thulium laser treatment of upper urinary tract carcinoma: a multi-institutional analysis of surgical and oncological outcomes. J Endourol 32(3):257\u2013263. \n                    https:\/\/doi.org\/10.1089\/end.2017.0915","journal-title":"J Endourol"},{"issue":"Suppl 1","key":"2232_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1100\/tsw.2004.49","volume":"4","author":"PE Clark","year":"2004","unstructured":"Clark PE, Streem SB (2004) Endourologic management of upper tract transitional cell carcinoma. Sci World J 4(Suppl 1):62\u201375. \n                    https:\/\/doi.org\/10.1100\/tsw.2004.49","journal-title":"Sci World J"},{"issue":"3","key":"2232_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1089\/end.2016.0475","volume":"31","author":"S Pan","year":"2017","unstructured":"Pan S, Smith AD, Motamedinia P (2017) Minimally invasive therapy for upper tract urothelial cell cancer. J Endourol 31(3):238\u2013245. \n                    https:\/\/doi.org\/10.1089\/end.2016.0475","journal-title":"J Endourol"},{"issue":"5","key":"2232_CR7","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1464-410X.2007.06870.x","volume":"99","author":"AN Argyropoulos","year":"2007","unstructured":"Argyropoulos AN, Tolley DA (2007) Upper urinary tract transitional cell carcinoma: current treatment overview of minimally invasive approaches. BJU Int 99(5):982\u2013987. \n                    https:\/\/doi.org\/10.1111\/j.1464-410X.2007.06870.x","journal-title":"BJU Int"},{"issue":"6","key":"2232_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/14737140.2017.1326823","volume":"17","author":"JD Raman","year":"2017","unstructured":"Raman JD, Park R (2017) Endoscopic management of upper-tract urothelial carcinoma. Expert Rev Anticancer Ther 17(6):545\u2013554. \n                    https:\/\/doi.org\/10.1080\/14737140.2017.1326823","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2232_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.urology.2008.06.026","volume":"73","author":"AR Rastinehad","year":"2009","unstructured":"Rastinehad AR, Ost MC, VanderBrink BA, Greenberg KL, El-Hakim A, Marcovich R, Badlani GH, Smith AD (2009) A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy? Urology 73(1):27\u201331. \n                    https:\/\/doi.org\/10.1016\/j.urology.2008.06.026","journal-title":"Urology"},{"issue":"7","key":"2232_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.urolonc.2019.02.004","volume":"37","author":"B Foerster","year":"2019","unstructured":"Foerster B, D\u2019Andrea D, Abufaraj M, Broenimann S, Karakiewicz PI, Roupret M, Gontero P, Lerner SP, Shariat SF, Soria F (2019) Endocavitary treatment for upper tract urothelial carcinoma: a meta-analysis of the current literature. Urol Oncol 37(7):430\u2013436. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2019.02.004","journal-title":"Urol Oncol"},{"key":"2232_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.urology.2016.09.039","volume":"99","author":"NM Donin","year":"2017","unstructured":"Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Said J, Raman SS, Holden S, Pantuck A, Belldegrun AS, Chamie K (2017) Sustained-release formulation of mitomycin C to the upper urinary tract using a thermosensitive polymer: a preclinical study. Urology 99:270\u2013277. \n                    https:\/\/doi.org\/10.1016\/j.urology.2016.09.039","journal-title":"Urology"},{"issue":"11","key":"2232_CR12","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.ejso.2016.08.008","volume":"42","author":"D Fang","year":"2016","unstructured":"Fang D, Seisen T, Yang K, Liu P, Fan X, Singla N, Xiong G, Zhang L, Li X, Zhou L (2016) A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 42(11):1625\u20131635. \n                    https:\/\/doi.org\/10.1016\/j.ejso.2016.08.008","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2232_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bju.13825","volume":"120","author":"A Kocot","year":"2017","unstructured":"Kocot A, Kalogirou C, Vergho D, Riedmiller H (2017) Long-term results of ileal ureteric replacement: a 25-year single-centre experience. BJU Int 120(2):273\u2013279. \n                    https:\/\/doi.org\/10.1111\/bju.13825","journal-title":"BJU Int"},{"issue":"9","key":"2232_CR14","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00345-015-1753-7","volume":"34","author":"L Villa","year":"2016","unstructured":"Villa L, Cloutier J, Letendre J, Ploumidis A, Salonia A, Cornu JN, Montorsi F, Traxer O (2016) Early repeated ureteroscopy within 6\u20138\u00a0weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol 34(9):1201\u20131206. \n                    https:\/\/doi.org\/10.1007\/s00345-015-1753-7","journal-title":"World J Urol"},{"issue":"3","key":"2232_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrurol.2015.24","volume":"12","author":"T Seisen","year":"2015","unstructured":"Seisen T, Colin P, Roupret M (2015) Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol 12(3):155\u2013166. \n                    https:\/\/doi.org\/10.1038\/nrurol.2015.24","journal-title":"Nat Rev Urol"},{"issue":"1","key":"2232_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupret","year":"2018","unstructured":"Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, Palou J, Shariat SF (2018) European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73(1):111\u2013122. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2017.07.036","journal-title":"Eur Urol"},{"issue":"2","key":"2232_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11934-013-0305-1","volume":"14","author":"P Smith","year":"2013","unstructured":"Smith P, Mandel J, Raman JD (2013) Conservative nephron-sparing treatment of upper-tract tumors. Curr Urol Rep 14(2):102\u2013108. \n                    https:\/\/doi.org\/10.1007\/s11934-013-0305-1","journal-title":"Curr Urol Rep"},{"issue":"8","key":"2232_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/jso.25456","volume":"119","author":"MD Wissing","year":"2019","unstructured":"Wissing MD, Santos F, Zakaria AS, O\u2019Flaherty A, Tanguay S, Kassouf W, Aprikian AG (2019) Short- and long-term survival has improved after radical cystectomy for bladder cancer in Quebec during the years 2000\u20132015. J Surg Oncol 119(8):1135\u20131144. \n                    https:\/\/doi.org\/10.1002\/jso.25456","journal-title":"J Surg Oncol"},{"issue":"3","key":"2232_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/107327481302000307","volume":"20","author":"MC Biagioli","year":"2013","unstructured":"Biagioli MC, Fernandez DC, Spiess PE, Wilder RB (2013) Primary bladder preservation treatment for urothelial bladder cancer. Cancer Control J Moffitt Cancer Cent 20(3):188\u2013199. \n                    https:\/\/doi.org\/10.1177\/107327481302000307","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"issue":"4","key":"2232_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3233\/blc-170134","volume":"3","author":"GW Moran","year":"2017","unstructured":"Moran GW, Li G, Robins DJ, Matulay JT, McKiernan JM, Anderson CB (2017) Systematic review and meta-analysis on the efficacy of chemotherapy with transurethral resection of bladder tumors as definitive therapy for muscle invasive bladder cancer. Bladder Cancer (Amst Neth) 3(4):245\u2013258. \n                    https:\/\/doi.org\/10.3233\/blc-170134","journal-title":"Bladder Cancer (Amst Neth)"},{"issue":"3","key":"2232_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.urology.2007.05.007","volume":"70","author":"D Leibovici","year":"2007","unstructured":"Leibovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, Grossman HB (2007) Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 70(3):473\u2013476. \n                    https:\/\/doi.org\/10.1016\/j.urology.2007.05.007","journal-title":"Urology"},{"issue":"1","key":"2232_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2001.19.1.89","volume":"19","author":"HW Herr","year":"2001","unstructured":"Herr HW (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19(1):89\u201393. \n                    https:\/\/doi.org\/10.1200\/JCO.2001.19.1.89","journal-title":"J Clin Oncol"},{"issue":"1","key":"2232_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1464-410X.2012.11762.x","volume":"112","author":"ZL Smith","year":"2013","unstructured":"Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ (2013) Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int 112(1):13\u201325. \n                    https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11762.x","journal-title":"BJU Int"},{"issue":"9","key":"2232_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859\u2013866. \n                    https:\/\/doi.org\/10.1056\/NEJMoa022148","journal-title":"N Engl J Med"},{"issue":"2","key":"2232_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","volume":"65","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S (2014) Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 65(2):350\u2013357. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2013.06.049","journal-title":"Eur Urol"},{"key":"2232_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.1629","author":"SB Williams","year":"2019","unstructured":"Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB (2019) Comparison of costs of radical cystectomy vs trimodal therapy for patients with localized muscle-invasive bladder cancer. JAMA Surg. \n                    https:\/\/doi.org\/10.1001\/jamasurg.2019.1629","journal-title":"JAMA Surg"},{"issue":"6","key":"2232_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","volume":"29","author":"A Choudhury","year":"2011","unstructured":"Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, Symonds P, Wylie JP, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke NW, Kiltie AE, Cowan RA (2011) Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 29(6):733\u2013738. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.31.5721","journal-title":"J Clin Oncol"},{"issue":"3","key":"2232_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","volume":"57","author":"MP Hagan","year":"2003","unstructured":"Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU (2003) RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57(3):665\u2013672","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2232_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","volume":"73","author":"DS Kaufman","year":"2009","unstructured":"Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, Zietman AL, Tanguay S, Sandler HM (2009) Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73(4):833\u2013837. \n                    https:\/\/doi.org\/10.1016\/j.urology.2008.09.036","journal-title":"Urology"},{"issue":"34","key":"2232_CR30","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32(34):3801\u20133809. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.57.5548","journal-title":"J Clin Oncol"},{"issue":"16","key":"2232_CR31","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA, Investigators BC (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366(16):1477\u20131488. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1106106","journal-title":"N Engl J Med"},{"issue":"9","key":"2232_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"T Mitin","year":"2013","unstructured":"Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL (2013) Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 14(9):863\u2013872. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70255-9","journal-title":"Lancet Oncol"},{"issue":"5","key":"2232_CR33","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","volume":"170","author":"AL Zietman","year":"2003","unstructured":"Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, Talcott JA, Shipley WU (2003) Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 170(5):1772\u20131776. \n                    https:\/\/doi.org\/10.1097\/01.ju.0000093721.23249.c3","journal-title":"J Urol"},{"issue":"11","key":"2232_CR34","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(11):1483\u20131492. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30616-2","journal-title":"Lancet Oncol"},{"issue":"3","key":"2232_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312\u2013322. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30065-7","journal-title":"Lancet Oncol"},{"issue":"1","key":"2232_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clgc.2018.09.021","volume":"17","author":"DM Jiang","year":"2019","unstructured":"Jiang DM, Jiang H, Chung PWM, Zlotta AR, Fleshner NE, Bristow RG, Berlin A, Kulkarni GS, Alimohamed NS, Lo G, Sridhar SS (2019) Neoadjuvant chemotherapy before bladder-sparing chemoradiotherapy in patients with nonmetastatic muscle-invasive bladder cancer. Clin Genitourin Cancer 17(1):38\u201345. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2018.09.021","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2232_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.juro.2010.09.015","volume":"185","author":"U Fedeli","year":"2011","unstructured":"Fedeli U, Fedewa SA, Ward EM (2011) Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 185(1):72\u201378. \n                    https:\/\/doi.org\/10.1016\/j.juro.2010.09.015","journal-title":"J Urol"},{"issue":"4","key":"2232_CR38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.juro.2012.06.029","volume":"188","author":"JJ Knoedler","year":"2012","unstructured":"Knoedler JJ, Boorjian SA, Kim SP, Weight CJ, Thapa P, Tarrell RF, Cheville JC, Frank I (2012) Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol 188(4):1115\u20131119. \n                    https:\/\/doi.org\/10.1016\/j.juro.2012.06.029","journal-title":"J Urol"},{"key":"2232_CR39","doi-asserted-by":"publisher","first-page":"702653","DOI":"10.1155\/2014\/702653","volume":"2014","author":"WM Bazzi","year":"2014","unstructured":"Bazzi WM, Kopp RP, Donahue TF, Bernstein M, Russo P, Bochner BH, Donat SM, Dalbagni G, Herr HW (2014) Partial cystectomy after neoadjuvant chemotherapy: Memorial Sloan Kettering Cancer Center contemporary experience. Int Sch Res Not 2014:702653. \n                    https:\/\/doi.org\/10.1155\/2014\/702653","journal-title":"Int Sch Res Not"},{"issue":"10","key":"2232_CR40","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.ejso.2013.04.006","volume":"39","author":"B Ma","year":"2013","unstructured":"Ma B, Li H, Zhang C, Yang K, Qiao B, Zhang Z, Xu Y (2013) Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes. Eur J Surg Oncol 39(10):1150\u20131156. \n                    https:\/\/doi.org\/10.1016\/j.ejso.2013.04.006","journal-title":"Eur J Surg Oncol"},{"issue":"3B","key":"2232_CR41","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1111\/j.1464-410X.2012.11438.x","volume":"111","author":"HM Bruins","year":"2013","unstructured":"Bruins HM, Wopat R, Mitra AP, Cai J, Miranda G, Skinner EC, Daneshmand S (2013) Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following partial cystectomy. BJU Int 111(3B):E37\u2013E42. \n                    https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11438.x","journal-title":"BJU Int"},{"issue":"3","key":"2232_CR42","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol 198(3):552\u2013559. \n                    https:\/\/doi.org\/10.1016\/j.juro.2017.04.086","journal-title":"J Urol"},{"issue":"9","key":"2232_CR43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","volume":"16","author":"TW Flaig","year":"2018","unstructured":"Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA (2018) NCCN guidelines insights: bladder cancer, Version 5.2018. J Natl Compr Cancer Netw 16(9):1041\u20131053. \n                    https:\/\/doi.org\/10.6004\/jnccn.2018.0072","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"2232_CR44","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.urology.2006.08.1057","volume":"68","author":"MA Swartz","year":"2006","unstructured":"Swartz MA, Porter MP, Lin DW, Weiss NS (2006) Incidence of primary urethral carcinoma in the United States. Urology 68(6):1164\u20131168. \n                    https:\/\/doi.org\/10.1016\/j.urology.2006.08.1057","journal-title":"Urology"},{"issue":"1","key":"2232_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1464-410X.2007.06901.x","volume":"100","author":"Y Smith","year":"2007","unstructured":"Smith Y, Hadway P, Ahmed S, Perry MJ, Corbishley CM, Watkin NA (2007) Penile-preserving surgery for male distal urethral carcinoma. BJU Int 100(1):82\u201387. \n                    https:\/\/doi.org\/10.1111\/j.1464-410X.2007.06901.x","journal-title":"BJU Int"},{"issue":"6","key":"2232_CR46","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3816\/CGC.2007.n.021","volume":"5","author":"JH Taylor","year":"2007","unstructured":"Taylor JH, Davis J, Schellhammer P (2007) Long-term follow-up of intravesical bacillus Calmette\u2013Guerin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. Clin Genitourin Cancer 5(6):386\u2013389. \n                    https:\/\/doi.org\/10.3816\/CGC.2007.n.021","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"2232_CR47","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/1097-0142(19930515)71:10<3102::AID-CNCR2820711034>3.0.CO;2-2","volume":"71","author":"AS Garden","year":"1993","unstructured":"Garden AS, Zagars GK, Delclos L (1993) Primary carcinoma of the female urethra. Results of radiation therapy. Cancer 71(10):3102\u20133108","journal-title":"Cancer"},{"issue":"5","key":"2232_CR48","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.eururo.2013.03.044","volume":"64","author":"G Gakis","year":"2013","unstructured":"Gakis G, Witjes JA, Comperat E, Cowan NC, De Santis M, Lebret T, Ribal MJ, Sherif AM (2013) EAU guidelines on primary urethral carcinoma. Eur Urol 64(5):823\u2013830. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2013.03.044","journal-title":"Eur Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02232-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02232-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02232-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T23:12:43Z","timestamp":1595718763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02232-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,27]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02232-z","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,27]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}